CereScan, Corp. Competitors

A global healthcare technology leader — boldly attacking the most challenging health problems facing humanity with innovations that transform lives.

BrainCheck is a digital health company powering positive progress in cognitive health. The BrainCheck Platform™ offers the most comprehensive digital cognitive toolset to promote proactive screening, detect early signs of decline, and personalize care planning – anytime, anywhere. Founded by renowned neuroscientists and technologists, including David Eagleman, PhD, our intuitive solutions transcend the limitations of traditional methods and expand access to cognitive care with the tap of a finger, from any device, in any location. Trusted by hundreds of leading providers and healthcare systems, our clinically-validated digital cognitive assessment and care planning tools fit seamlessly into workflows, including EHR integration, delivering actionable insights with ease. Earlier, better, longer brain health begins with empowering action: Don’t raincheck the BrainCheck™. To learn more, visit braincheck.com.

BrainScope is a leading neurotechnology company advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment (both brain bleeds and concussions) with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs, substantial reductions in patient length of stay in emergency departments, and high utility for concussion clinics, personal injury cases and sports. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and others.